FCF Biotech Venture Capital Monitor – USA 11/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 11/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of November 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 21,391m
  • Compared to November 2022 the financing volume decreased by roughly 28% (29,739m vs. 21,391m)
  • The top 5 deals exceed USD 273m each, the largest transaction amounted to USD 401m with ElevateBio
  • Terremoto Biosciences has the highest transaction Volume of USD 175m in November, followed by Kyverna USD 152m and Cognito Therapeutics USD 129m
  • ARCH Venture Partners (USA) is leading the Top 5 Investors (by deal volume), followed by RA Capital Management (USA) and OrbiMed (USA)
  • As an indication oncology records the highest investment activity

To access the full report, please click here.

By Mathias Klozenbücher und Johannes Link.